Literature DB >> 26903214

Effects of Pulsed Electromagnetic Fields on Return to Sports After Arthroscopic Debridement and Microfracture of Osteochondral Talar Defects: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Mikel L Reilingh1, Christiaan J A van Bergen2, Rogier M Gerards2, Inge C van Eekeren2, Rob J de Haan3, Inger N Sierevelt4, Gino M M J Kerkhoffs2, Rover Krips5, Duncan E Meuffels6, C N van Dijk2, Leendert Blankevoort2.   

Abstract

BACKGROUND: Osteochondral defects (OCDs) of the talus usually affect athletic patients. The primary surgical treatment consists of arthroscopic debridement and microfracture. Various possibilities have been suggested to improve the recovery process after debridement and microfracture. A potential solution to obtain this goal is the application of pulsed electromagnetic fields (PEMFs), which stimulate the repair process of bone and cartilage. HYPOTHESIS: The use of PEMFs after arthroscopic debridement and microfracture of an OCD of the talus leads to earlier resumption of sports and an increased number of patients that resume sports. STUDY
DESIGN: Randomized controlled trial; Level of evidence, 1.
METHODS: A total of 68 patients were randomized to receive either PEMFs (n = 36) or placebo (n = 32) after arthroscopic treatment of an OCD of the talus. The primary outcomes (ie, the number of patients who resumed sports and time to resumption of sports) were analyzed with Kaplan-Meier curves as well as Mann-Whitney U, chi-square, and log-rank tests. Secondary functional outcomes were assessed with questionnaires (American Orthopaedic Foot and Ankle Society ankle-hindfoot score, Foot and Ankle Outcome Score, EuroQol, and numeric rating scales for pain and satisfaction) at multiple time points up to 1-year follow-up. To assess bone repair, computed tomography scans were obtained at 2 weeks and 1 year postoperatively.
RESULTS: Almost all outcome measures improved significantly in both groups. The percentage of sport resumption (PEMF, 79%; placebo, 80%; P = .95) and median time to sport resumption (PEMF, 17 weeks; placebo, 16 weeks; P = .69) did not differ significantly between the treatment groups. Likewise, there were no significant between-group differences with regard to the secondary functional outcomes and the computed tomography results.
CONCLUSION: PEMF does not lead to a higher percentage of patients who resume sports or to earlier resumption of sports after arthroscopic debridement and microfracture of talar OCDs. Furthermore, no differences were found in bone repair between groups. REGISTRATION: Netherlands Trial Register NTR1636.
© 2016 The Author(s).

Entities:  

Keywords:  ankle; arthroscopic debridement and microfracture; articular cartilage; biophysical stimulation; osteochondral defect; pulsed electromagnetic fields

Mesh:

Year:  2016        PMID: 26903214     DOI: 10.1177/0363546515626544

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  16 in total

1.  Reply to the letter to the editor: comment on "No superior treatment for primary osteochondral defects of the talus".

Authors:  Jari Dahmen; Kaj T A Lambers; Mikel L Reilingh; Christiaan J A van Bergen; Sjoerd A S Stufkens; Gino M M J Kerkhoffs
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-09-16       Impact factor: 4.342

2.  Comment on "No superior treatment for primary osteochondral defects of the talus. Dahmen J, et al. KSSTA 2017 Jun 27 PMID:28656457".

Authors:  Christian Candrian; Alberto Grassi; Giuseppe Filardo; Francesca Vannini
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-09-04       Impact factor: 4.342

Review 3.  Electrical stimulation-based bone fracture treatment, if it works so well why do not more surgeons use it?

Authors:  Mit Balvantray Bhavsar; Zhihua Han; Thomas DeCoster; Liudmila Leppik; Karla Mychellyne Costa Oliveira; John H Barker
Journal:  Eur J Trauma Emerg Surg       Date:  2019-04-06       Impact factor: 3.693

4.  Should Arthroscopic Bone Marrow Stimulation Be Used in the Management of Secondary Osteochondral Lesions of the Talus? A Systematic Review.

Authors:  Zaki Arshad; Aiman Aslam; Adil M Iqbal; Maneesh Bhatia
Journal:  Clin Orthop Relat Res       Date:  2022-02-07       Impact factor: 4.755

5.  Computed tomography analysis of osteochondral defects of the talus after arthroscopic debridement and microfracture.

Authors:  M L Reilingh; C J A van Bergen; L Blankevoort; R M Gerards; I C M van Eekeren; G M M J Kerkhoffs; C N van Dijk
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-12-28       Impact factor: 4.342

Review 6.  Establishing the Basis for Mechanobiology-Based Physical Therapy Protocols to Potentiate Cellular Healing and Tissue Regeneration.

Authors:  Joanna L Ng; Mariana E Kersh; Sharon Kilbreath; M Knothe Tate
Journal:  Front Physiol       Date:  2017-06-06       Impact factor: 4.566

Review 7.  No superior surgical treatment for secondary osteochondral defects of the talus.

Authors:  Kaj T A Lambers; Jari Dahmen; Mikel L Reilingh; Christiaan J A van Bergen; Sjoerd A S Stufkens; Gino M M J Kerkhoffs
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-07-07       Impact factor: 4.342

Review 8.  No superior treatment for primary osteochondral defects of the talus.

Authors:  Jari Dahmen; Kaj T A Lambers; Mikel L Reilingh; Christiaan J A van Bergen; Sjoerd A S Stufkens; Gino M M J Kerkhoffs
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-06-27       Impact factor: 4.342

9.  The subchondral bone healing after fixation of an osteochondral talar defect is superior in comparison with microfracture.

Authors:  Mikel L Reilingh; Kaj T A Lambers; Jari Dahmen; Kim T M Opdam; Gino M M J Kerkhoffs
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-07-27       Impact factor: 4.342

10.  Return to sports after arthroscopic debridement and bone marrow stimulation of osteochondral talar defects: a 5- to 24-year follow-up study.

Authors:  I C M van Eekeren; C J A van Bergen; I N Sierevelt; M L Reilingh; C N van Dijk
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-02-04       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.